Diagnosis and prognosis of inflammatory bowel diseases: modern view

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

About 5% of the population suffer from chronic diarrhea. Intestinal infections are the most common cause of diarrheal syndrome. However, if they are excluded, it is necessary to check for other possible reasons: vascular, oncological, rheumatic, drug-induced, radiation diseases and other gastroenterological pathology except from inflammatory bowel diseases.

When predicting and detrcting new predictors of unfavorable outcomes and progression of inflammatory bowel diseases, special attention has been recently paid to serological markers and genetic research, which have not yet entered clinical practice due to their high cost.

Inflammatory bowel diseases is a diagnosis of exclusion, which is made after a comprehensive assessment of clinical, laboratory, endoscopic, and morphological data. In case of the development of complications, it needs to investigate new available prognostic markers of inflammatory bowel diseases course.

Full Text

Restricted Access

About the authors

Igor G. Bakulin

North-Western State Medical University named after I.I. Mechnikov

Email: igbakulin@yandex.ru
ORCID iD: 0000-0002-6151-2021
SPIN-code: 5283-2032
Scopus Author ID: 6603812937
ResearcherId: P-4453-2014

MD, Dr. Sci. (Med.), Professor

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015

Irina A. Rasmagina

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: irenerasmagina@gmail.com
ORCID iD: 0000-0003-3525-3289
SPIN-code: 6634-0342

postgraduate student of the Chair of the Propedeutics of Internal Diseases, Gastroenterology and Dietology n.a. S.M. Riss

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015

Maria I. Skalinskaya

North-Western State Medical University named after I.I. Mechnikov

Email: mskalinskaya@yahoo.com
ORCID iD: 0000-0003-0769-8176
SPIN-code: 2596-5555

MD, Cand. Sci. (Med.), Assistant Professor

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015

References

  1. Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4):322–337. doi: 10.1016/j.crohns.2013.01.010
  2. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. doi: 10.1016/S0140-6736(17)32448-0
  3. Knyazev OV, Shkurko TV, Fadeyeva NA, et al. Epidemiology of chronic inflammatory bowel disease. Yesterday, today, tomorrow. Experimental and Clinical Gastroenterology. 2017;139(3):4–12. (In Russ.)
  4. Bakulin IG, Zhigalova TN, Latariya EhL, et al. Experience of introduction of the Federal Registry of patients with inflammatory bowel diseases in Saint-Petersburg. Farmateka. 2017;(S5):56–59. (In Russ.)
  5. Maev IV, Shelygin YuA, Skalinskaya MI, et al. The pathomorphosis of inflammatory bowel diseases. Annals of the Russian Academy of Medical Sciences. 2020;75(1):27–35. (In Russ.). doi: 10.15690/vramn1219
  6. Klinicheskie rekomendatsii «Yazvennyy kolit» [Internet]. Available from: https://legalacts.ru/doc/klinicheskie-rekomendatsii-iazvennyi-kolit-utv-minzdravom-rossii. Accessed: 18.09.2021. (In Russ.)
  7. Park SH, Yang SK, Park SK, et al. Atypical distribution of inflammation in newly diagnosed ulcerative colitis is not rare. Can J Gastroenterol Hepatol. 2014;28(3):125–130. doi: 10.1155/2014/834512
  8. Kim B, Barnett JL, Kleer CG, Appelman HD. Endoscopic and histological patchiness in treated ulcerative colitis. Am J Gastroenterol. 1999;94(11):3258–3262. doi: 10.1111/j.1572-0241.1999.01533.x
  9. Abdelrazeq AS, Wilson TR, Leitch DL, et al. Ileitis in ulcerative colitis: is it a backwash? Dis Colon Rectum. 2005;48(11):2038–2046. doi: 10.1007/s10350-005-0160-3
  10. Ivashkin VT, Shelygin YuA, Abdulganieva DI, et al. Crohn’s disease. Clinical recommendations (preliminary version). Koloproktologia. 2020;19(2(72)):8–38. (In Russ.). doi: 10.33878/2073-7556-2020-19-2-8-38
  11. Lapin SV, Totolyan AA. Immunologicheskaya laboratornaya diagnostika autoimmunnykh zabolevanii. Saint Petersburg; 2010. (In Russ.)
  12. Fairclough E, Cairns E, Hamilton J, Kelly C. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med (Lond). 2009;9(1):30–33. doi: 10.7861/clinmedicine.9-1-30
  13. Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig Dis. 2010;28(3):418–423. doi: 10.1159/000320396
  14. Lozoya Angulo ME, de Las Heras Gómez I, Martinez Villanueva M, et al. Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders. Gastroenterol Hepatol. 2017;40(3):125–131. doi: 10.1016/j.gastrohep.2016.04.009
  15. Dai C, Jiang M, Sun MJ, Cao Q. Fecal lactoferrin for assessment of inflammatory bowel disease activity: a systematic review and meta-analysis. J Clin Gastroenterol. 2020;54(6):545–553. doi: 10.1097/MCG.0000000000001212
  16. Rubio MG, Amo-Mensah K, Gray JM, et al. Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2019;10(5):54–63. doi: 10.4291/wjgp.v10.i554
  17. Skalinskaya MI, Skazyvaeva EV, Bakulin IG, et al. The problem of undifferentiated inflammatory bowel disease: from world views to own experience of artificial neural networks application. Preventive and clinical medicine. 2019;2(71):74–81 (In Russ.)
  18. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A–36A. doi: 10.1155/2005/269076
  19. Burisch J, Pedersen N, Čuković-Čavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2014;63(4):588–597. doi: 10.1136/gutjnl-2013-304636
  20. Burisch J, Zammit SC, Ellul P, et al. Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study. J Gastroenterol Hepatol. 2019;34(6):996–1003. doi: 10.1111/jgh.14563
  21. Melmed GY, Elashoff R, Chen GC, et al. Predicting a change in diagnosis from ulcerative colitis to Crohn’s disease: a nested, case-control study. Clin Gastroenterol Hepatol. 2007;5(5):602–608;quiz 525. doi: 10.1016/j.cgh.2007.02.015
  22. Miehlke S, Verhaegh B, Tontini GE,et al. Microscopic colitis: pathophysiology and clinical management. Lancet Gastroenterol Hepatol. 2019;4(4):305–314. doi: 10.1016/S2468-1253(19)30048-2
  23. Korochanskaya NV, Durleshter VM. Ishemicheskiy kolit: sovremennye podkhody k diagnostike i lecheniyu: uchebno-metodicheskoe posobie dlya vrachey. Moscow: Prima Print; 2016. (In Russ.)
  24. Hansen KJ, Wilson DB, Craven TE, et al. Mesenteric artery disease in the elderly. J Vasc Surg. 2004;40(1):45–52. doi: 10.1016/j.jvs.2004.03.022
  25. Munipalle PC, Garud T, Light D. Diaphragmatic disease of the colon: systematic review. Colorectal Dis. 2013;15(9):1063–1069. doi: 10.1111/codi.12218
  26. Tandon P, Bourassa-Blanchette S, Bishay K, et al. The Risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. J Immunother. 2018;41(3):101–108. doi: 10.1097/CJI.0000000000000213
  27. Wright AP, Piper MS, Bishu S, Stidham RW. Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2019;49(12):1474–1483. doi: 10.1111/apt.15263
  28. Bavi P, Butler M, Serra S, Chetty R. Immune modulator-induced changes in the gastrointestinal tract. Histopathology. 2017;71(3):494–496. doi: 10.1111/his.13224
  29. Gecse KB, Vermeire S. Differential diagnosis of inflammatory bowel disease: imitations and complications. Lancet Gastroenterol Hepatol. 2018;3(9):644–653. doi: 10.1016/S2468-1253(18)30159-6
  30. Calmet FH, Yarur AJ, Pukazhendhi G, et al. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation. Ann Gastroenterol. 2015;28(3):366–373.
  31. Topchij TB, Sycheva IV, Ruhadze GO, et al. Luchevye proktity: posobie dlja vrachej. Moscow: Prima Print; 2019. (In Russ.)
  32. Nelamangala Ramakrishnaiah VP, Krishnamachari S. Chronic haemorrhagic radiation proctitis: A review. World J Gastrointest Surg. 2016;8(7):483–491. doi: 10.4240/wjgs.v8.i7.483
  33. Zabolevaemost’ naselenija otdel’nymi infekcionnymi zabolevanijami v 2016 godu [Internet]. Federal’naja sluzhba gosudarstvennoj statistiki. Available from: http://www.gks.ru/bgd/regl/b17_01/IssWWW.exe/Stg/d01/3-3.doc. Accessed: 18.09.2021. (In Russ.)
  34. Klinicheskij protokol diagnostiki i lechenija. Diareja i gastrojenterit predpolozhitel’no infekcionnogo proishozhdenija [Internet]. Available from: http://www.rcrz.kz/docs/clinic_protocol/2015/285.pdf. Accessed: 18.10.2021. (In Russ.)
  35. Hajifathalian K, Mahadev S, Schwartz RE, et al. SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant. World J Gastroenterol. 2020;26(14):1546–1553. doi: 10.3748/wjg.v26.i14.1546
  36. Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med. 2006;354(2):119–130. doi: 10.1056/NEJMoa051331
  37. Stermer E, Lubezky A, Potasman I, et al. Is traveler’s diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis. 2006;43(7):898–901. doi: 10.1086/507540
  38. Oh SJ, Lee CK, Kim YW, et al. True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares: the 10-year experience of an academic referral inflammatory bowel disease center. Scand J Gastroenterol. 2019;54(8):976–983. doi: 10.1080/00365521.2019.1646798
  39. Beswick L, Ye B, van Langenberg DR. Toward an algorithm for the diagnosis and management of CMV in patients with colitis. Inflamm Bowel Dis. 2016;22(12):2966–2976. doi: 10.1097/MIB.0000000000000958
  40. Zagórowicz E, Bugajski M, Wieszczy P, et al. Cytomegalovirus infection in ulcerative colitis is related to severe inflammation and a high count of cytomegalovirus-positive cells in biopsy is a risk factor for colectomy. J Crohns Colitis. 2016;10(10):1205–1211. doi: 10.1093/ecco-jcc/jjw071
  41. Störkmann H, Rödel J, Stallmach A, Reuken PA. Are CMV-predictive scores in inflammatory bowel disease useful in clinical practice? Z Gastroenterol. 2020;58(9):868–871. doi: 10.1055/a-1221-5463
  42. Shivaji UN, Sharratt CL, Thomas T, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(6):664–680. doi: 10.1111/apt.15097
  43. Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver. 2014;8(1):1–6. doi: 10.5009/gnl.2014.8.1.1
  44. Furuya-Kanamori L, Stone JC, Clark J, et al. Comorbidities, exposure to medications, and the risk of community-acquired clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36(2):132–141. doi: 10.1017/ice.2014.39
  45. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742–748. doi: 10.1093/jac/dkr508
  46. Federal’nye klinicheskie rekomendacii po diagnostike i lecheniju sistemnyh vaskulitov. 2013 [Internet]. Available from: https://www.mrckb.ru/files/vaskulity.doc. Accessed: 18.10.2021. (In Russ.)
  47. Levine SM, Hellmann DB, Stone JH. Gastrointestinal involvement in polyarteritis nodosa (1986-2000): presentation and outcomes in 24 patients. Am J Med. 2002;112(5):386–391. doi: 10.1016/s0002-9343(01)01131-7
  48. Klinicheskie rekomendatsii “Bolezn’ Bekhcheta”. 2018 [Internet]. Available from: https://legalacts.ru/doc/klinicheskie-rekomendatsii-bolezn-bekhcheta-bb-utv-minzdravom-rossii/. Accessed: 18.09.2021. (In Russ.)
  49. Feng R, Chao K, Chen SL, et al. Heat shock protein family A member 6 combined with clinical characteristics for the differential diagnosis of intestinal Behçet’s disease. J Dig Dis. 2018;19(6):350–358. doi: 10.1111/1751-2980.12613
  50. Ye JF, Guan JL. Differentiation between intestinal Behçet’s disease and Crohn’sdisease based on endoscopy. Turk J Med Sci. 2019;49(1):42–49. doi: 10.3906/sag-1807-67
  51. Rustom LBO, Sharara AI. The Natural history of colonic diverticulosis: Much ado about nothing? Inflamm Intest Dis. 2018;3(2):69–74. doi: 10.1159/000490054
  52. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010;375(9719):1030–1047. doi: 10.1016/S0140-6736(10)60353-4
  53. Theede K, Holck S, Ibsen P, et al. Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2016;22(5):1042–1048. doi: 10.1097/MIB.0000000000000736
  54. Mak WY, Buisson A, Andersen MJ Jr, et al. Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis. Dig Dis Sci. 2018;63(5):1294–1301. doi: 10.1007/s10620-018-4980-0
  55. Ye YL, Yin J, Hu T, et al. Increased circulating circular RNA_103516 is a novel biomarker for inflammatory bowel disease in adult patients. World J Gastroenterol. 2019;25(41):6273–6288. doi: 10.3748/wjg.v25.i41.6273
  56. Xu Y, Xu X, Ocansey DKW, et al. CircRNAs as promising biomarkers of inflammatory bowel disease and its associated-colorectal cancer. Am J Transl Res. 2021;13(3):1580–1593.
  57. Edwards SJ, Barton S, Bacelar M, et al. Prognostic tools for identification of high risk in people with Crohn’s disease: systematic review and cost-effectiveness study. Health Technol Assess. 2021;25(23):1–138. doi: 10.3310/hta25230
  58. Verbeeten DS. Genetic and serological markers associated with pouchitis and a Crohn’s disease-like phenotype after pelvic pouch surgery for ulcerative colitis. [dissertation] Toronto: University of Tornonto; 2009.
  59. Morilla I, Uzzan M, Laharie D, et al. Colonic MicroRNA profiles, identified by a deep learning algorithm, that predict responses to therapy of patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17(5):905–913. doi: 10.1016/j.cgh.2018.08.068

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bakulin I.G., Rasmagina I.A., Skalinskaya M.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 71733 от 08.12.2017.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies